11:15 AM EDT, 07/22/2024 (MT Newswires) -- Bausch + Lomb's ( BLCO ) Q2 revenue is expected to grow nearly 15% year-over-year, helped by acquisitions, though the quarter likely continued to be "influenced" by foreign exchange headwinds, RBC said Monday.

The eye health company is scheduled to report Q2 results July 31. RBC raised its revenue outlook to $1.19 billion from $1.18 billion. The market consensus is for $1.17 billion, the brokerage said.

RBC projects FX headwinds at $20 million to $25 million in Q2 as the headwinds have "worsened" since the company's Q1 earnings call in February, analyst Douglas Miehm said in a note to clients.

In the upcoming earnings, the firm expects the focus to be on Bausch + Lomb's ( BLCO ) dry-eye disease Rx drugs, new launches, and the impact from a recall in the surgical segment, according to the note.

RBC raised its price target on the company's stock to $20 from $18, with an outperform rating.

Price: 17.23, Change: +0.25, Percent Change: +1.47